Introduction: The number of patients requiring anticoagulation, e.g., for cardiovascular diseases, is increasing, even in patients with immune thrombocytopenia (ITP). However, detailed guidelines and
The gut microbiome is clearly linked to the development of various autoimmune diseases, however, its association with immune thrombocytopenia (ITP) is less well understood. The current study collected
Immune thrombocytopenia (ITP) is an autoimmune disease with a mild to severe risk of bleeding complications. First line treatment includes corticosteroids, immunoglobulins, or other. In this large coh
Romiplostim is recommended for the second- and third-line treatment of primary immune thrombocytopenia (ITP). We conducted a large, single-arm study (clinicaltrials.gov; NCT00508820) with broad entry
Report of Immune Thrombocytopenia Treatment Market is covering the summarized study of several factors encouraging the growth of the market such as market size, market type, major regions and end user
